Provider Briefing: Alvesco Availability in 2026

Alvesco (Ciclesonide) remains an important option in the inhaled corticosteroid (ICS) landscape for asthma maintenance therapy. However, ongoing availability challenges mean that prescribers need to be aware of the current supply picture and prepared with alternatives when patients can't fill their prescriptions.

This briefing covers the current status, prescribing implications, and practical tools to help your patients access their medication.

Current Supply Timeline

Alvesco has not been formally listed on the FDA Drug Shortage Database as of early 2026. However, clinicians and patients consistently report difficulty filling prescriptions at retail pharmacies. The key factors:

• 2006: FDA approval of Ciclesonide inhalation aerosol (Alvesco) for asthma maintenance in patients ≥12 years
• 2018: AstraZeneca divested Alvesco to Covis Pharma B.V., creating a transition in distribution networks
• 2024-present: Retail pharmacy stocking of Alvesco has declined as the ICS market shifted toward generic Fluticasone HFA following Flovent's discontinuation
• 2026: Alvesco remains brand-only with no generic Ciclesonide inhaler approved. Earliest possible generic entry is ~2028

Prescribing Implications

When prescribing Alvesco in the current environment, consider these factors:

Formulary and Prior Authorization

Alvesco is covered by approximately 77% of commercial insurance plans, but it is frequently placed in Tier 3 or higher. Many payers require:

• Step therapy: Trial and failure of a preferred ICS (usually generic Fluticasone or Budesonide) before Alvesco is approved
• Prior authorization: Documentation of medical necessity, often requiring evidence that alternatives were tried
• Medicare Part D: Coverage is inconsistent — many Medicare plans do not include Alvesco on their formularies

Clinical Considerations for Ciclesonide

Ciclesonide's prodrug design offers distinct advantages for specific patient populations:

• Lower oropharyngeal deposition: Because Ciclesonide activates in the lungs via esterases, it has a lower rate of oropharyngeal candidiasis compared to Fluticasone and Budesonide
• Patients with prior oral thrush: Ciclesonide may be clinically preferred for patients who have experienced ICS-induced candidiasis with other agents
• Systemic bioavailability: Des-ciclesonide has high protein binding (~99%), resulting in lower systemic exposure — relevant for patients on higher ICS doses or those concerned about systemic steroid effects

For a detailed pharmacology review, see our mechanism of action explainer.

Availability Picture

The practical availability situation in 2026:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not carry Alvesco as standard inventory due to lower demand relative to Fluticasone and Budesonide products.
• Independent pharmacies: More likely to special-order, but availability depends on distributor stock
• Specialty/mail-order pharmacies: Generally more reliable for brand-only products
• Covis Transition Pharmacy Program: Manufacturer-sponsored home delivery for $60 per fill (cash-paying patients)

Cost and Access Overview

Understanding the cost landscape helps set patient expectations:

• Average cash price: $275-$411 per inhaler (6.1 gm, 60 inhalations)
• Alvesco Savings Card (commercially insured): Reduces out-of-pocket to as low as $0, max savings $525/Rx. Not available for government insurance (Medicare, Medicaid, TRICARE, VA).
• Covis Patient Assistance Program: Provides Alvesco at no charge for eligible uninsured/underinsured patients
• Patient Access Network (PAN) Foundation: Copay assistance for insured patients at 400-500% FPL
• Discount cards (SingleCare, GoodRx): ~$270 per inhaler

For a comprehensive cost guide, see our provider guide to helping patients save on Alvesco.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers allows your team to check real-time pharmacy stock for Alvesco and direct patients to pharmacies that have it available. This can reduce call-backs, rescheduled appointments, and patient frustration from unfilled prescriptions.

Manufacturer Resources

• Alvesco HCP portal: hcp.alvesco.us — clinical resources, dosing information, and sample ordering
• Savings card enrollment: alvesco.us/savings-card
• Patient assistance applications: Available through Covis Pharma (1-877-411-2510)

Therapeutic Alternatives

When Alvesco is unavailable or inaccessible, consider these evidence-based alternatives:

• Generic Fluticasone Propionate HFA: Most accessible and affordable ICS. Widely stocked. Cash price $25-$60.
• Qvar RediHaler (Beclomethasone): Another prodrug ICS with breath-actuated delivery. May offer similar tolerability profile.
• Pulmicort Flexhaler (Budesonide): DPI option. Generic inhalation suspension available for nebulizer use.
• Asmanex Twisthaler/HFA (Mometasone): Once-daily dosing option for appropriate patients.

For a detailed clinical comparison, see alternatives to Alvesco.

Looking Ahead

Key developments to watch:

• Generic Ciclesonide inhaler: No ANDA approvals yet, but earliest entry could come around 2028
• Market dynamics: The ICS market continues to consolidate around generic Fluticasone HFA and combination products. Alvesco's niche position may become more constrained.
• Covis Pharma distribution: Watch for any changes in the manufacturer's distribution strategy that could improve or further limit retail availability

Final Thoughts

Alvesco remains a clinically valuable ICS option, particularly for patients prone to oropharyngeal candidiasis or those requiring lower systemic steroid exposure. However, its brand-only status and limited retail availability require proactive prescribing strategies.

Use Medfinder for Providers to help patients locate pharmacies with stock, familiarize your team with the manufacturer assistance programs, and maintain a clear alternative pathway when Alvesco can't be filled.